Antiviral therapy completion and response rates among hepatitis c patients with and without schizophrenia

Schizophrenia Bulletin

Volumn 36, Issue 1, 2010, Pages 165-172

  Huckans, Marilyn ^a,b,c   Mitchell, Alex ^a,b   Ruimy, Samantha ^a,b   Loftis, Jennifer ^a,b,c,d   Hauser, Peter ^a,b,c,d  

^a Northwest Hepatitis C Resource Center   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Department of Psychiatry ^*  (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adverse effects; Interferon; Mental disorders; Psychotic disorders

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CONSENSUS INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SARCOIDOSIS; SCHIZOPHRENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VETERAN;

AGED; ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LONG-TERM CARE; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PATIENT CARE TEAM; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 73949159165     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn065     Document Type: Article

References (23)

1. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hHepatitis C: 2002-June 10-12. Hepatology. 2002;36: S3-S20.
2. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41(1):88-96.
3. Osher FC, Goldberg RW, McNary SW, et al. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003;54:842-847.
4. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31-37.
5. Huckans MS, Blackwell AD, Harms TA, Hauser P. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv. 2006; 57:403-406. (Pubitemid 43364194)
6. Rowan PJ, Tabasi S, Abdul-Latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004;38:530-534.
7. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719-734.
8. Rigsby M, Burgess J, Davey V, et al. Patients with chronic hepatitis C: VA treatment recommendations, version 5. 0. Fed Pract. 2003;20:1-33.
9. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U. S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772-1779.
10. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-758.
11. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389.
12. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001;96:157-164.
13. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with inter-feron alfa and ribavirin in psychiatric risk groups. Hepatol-ogy. 2003;37:443-451.
14. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat. 2006;13:235-241.
15. Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry. 2000; 33:72-74.
16. Mistler LA, Brunette MF, Rosenberg SD, Vidaver RM, Luckoor R, Iber M. Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha. Int J Psychiatry Med. 2006;36:449-455.
17. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Seraq HB. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Arlington, VA: American Psychiatric Association; 2000.
18. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155-174. (Pubitemid 43213901)
19. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C treatment for people with severe mental illness. Psychosomatics. 2006;47:93-107.
20. Rosenberg S, Brunette M, Oxman T, et al. The STIRR model of best practices for blood-borne diseases among clients with serious mental illness. Psychiatr Serv. 2004;55:660-664.
21. Kizer E, Whitehead A, Indest D, Hauser P. Efficacy of group education in veterans with hepatitis C. Fed Pract. 2006; 23(12):50-57.
22. Hadziyannis SJ, Settec H, Jr, Morgan TR, et al. Peginterfer-on-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ri-bavirin dose. Ann Intern Med. 2004;140:346-355.
23. Manns MP, McHutchison JG, Gordon SC, et al. Peginterfer-on alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.